Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasuya, H.
Right arrow Articles by Tanabe, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasuya, H.
Right arrow Articles by Tanabe, K. K.
[Cancer Research 64, 2561-2567, April 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Selectivity of an Oncolytic Herpes Simplex Virus for Cells Expressing the DF3/MUC1 Antigen

Hideki Kasuya, Timothy M. Pawlik, John T. Mullen, James M. Donahue, Hideo Nakamura, Soundararajalu Chandrasekhar, Hiroshi Kawasaki, Enid Choi and Kenneth K. Tanabe

Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Replication-conditional viruses destroy tumors in a process referred to as viral oncolysis. An important prerequisite for this cancer therapy strategy is use of viruses that replicate preferentially in neoplastic cells. In this study the DF3/MUC1 promoter/enhancer sequence is used to regulate expression of {gamma}134.5 to drive replication of a Herpes simplex virus 1 (HSV-1) mutant (DF3{gamma}34.5) preferentially in DF3/MUC1-positive cells. HSV-1 {gamma}134.5 functions to dephosphorylate elongation initiation factor 2{alpha}, which is an important step for robust HSV-1 replication. After DF3{gamma}34.5 infection of cells, elongation initiation factor 2{alpha} phosphatase activity and viral replication were observed preferentially in DF3/MUC1-positive cells but not in DF3/MUC1-negative cells. Regulation of {gamma}134.5 function results in preferential replication in cancer cells that express DF3/MUC1, restricted biodistribution in vivo, and less toxicity as assessed by LD50. Preferential replication of DF3{gamma}34.5 was observed in DF3/MUC1-positive liver tumors after intravascular perfusion of human liver specimens. DF3{gamma}34.5 was effective against carcinoma xenografts in nude mice. Regulation of {gamma}134.5 by the DF3/MUC1 promoter is a promising strategy for development of HSV-1 mutants for viral oncolysis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Viruses have evolved extremely efficient mechanisms to infect cells, subvert cell defenses, deliver their genetic payload, express viral genes, and produce progeny virions. Most viruses used in clinical trials of gene therapy have been rendered replication-defective by genetic engineering such that they serve mainly as gene delivery vehicles and do not replicate outside of specialized packaging cell lines (1) . There has been growing interest, however, in relying on the efficiency of viral replication itself as a means to destroy cancer cells in a process referred to as viral oncolysis (2) . The safety and efficacy of this approach are dependent on selective viral replication in cancer cells rather than in normal cells.

Several strategies have been explored to restrict viral replication to neoplastic cells, including use of tumor-associated promoters to regulate expression of genes critical for viral replication. A promoter/enhancer sequence for the prostate-specific antigen (PSA) gene has been used to regulate adenoviral E1A expression to restrict its replication to PSA-positive cells (3) . A promoter sequence of the {alpha}-fetoprotein gene has been used to regulate expression of both E1A and E1B55kD in an adenoviral mutant that replicates selectively in tumors that express {alpha}-fetoprotein (4) . The E2F-responsive B-myb promoter has been used to regulate expression of a gene critical for replication of Herpes simplex virus 1 (HSV-1; Ref. 5 ).

DF3/MUC1 is a tumor-associated antigen that is overexpressed on many human carcinomas, including breast, pancreatic, and colon cancer (6, 7, 8) . DF3/MUC1 transcript overexpression is observed in breast cancer (9) , and the 5' flanking region of the gene has been characterized (10) . DF3/MUC1 gene expression is regulated by sequences between positions –598 and –485 bp upstream from the transcription start site. This promoter/enhancer has been used to regulate expression of E1A in an adenoviral mutant, Ad.DF3-E1, which replicates preferentially in DF3/MUC1-positive cancer cells (11) .

HSV-1 is an effective oncolytic virus in animal models (12, 13, 14) , and clinical studies of HSV-1 for oncolysis have been conducted. G207 is a replication-conditional HSV-1 mutant that has been administered to patients with recurrent malignant glioma (15) . The HSV-1 mutant 1716 is defective in expression of HSV-1 {gamma}134.5 (16) and has been administered to patients with recurrent malignant glioma in a clinical trial (17) .

We have previously demonstrated that HSV-1 mutants defective in viral ribonucleotide reductase replicate preferentially in colon cancer liver metastases rather than normal liver because of higher mitotic activity and higher levels of functionally complementing cellular ribonucleotide reductase in the metastases (18) . The destruction of these liver tumors is a result of viral replication rather than host-immune responses (19 , 20) . In this study we constructed and characterized a mutant HSV-1 in which the {gamma}134.5 gene is regulated by a DF3/MUC1 promoter. Regulation of HSV-1 {gamma}134.5 function results in preferential viral replication and oncolysis in cancer cells that express DF3/MUC1, restricted biodistribution in vivo, and less toxicity as assessed by LD50. This HSV-1 mutant was effective against carcinoma xenografts in nude mice.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cells and Viruses.
Vero African Green Monkey kidney cells were obtained from American Type Culture Collection (Manassas, VA). MC26 mouse colon carcinoma cells were obtained from the National Cancer Institute Tumor Repository (Frederick, MD). A375 human melanoma cells were provided by Isaiah Fidler (M. D. Anderson Cancer Center, Houston, TX), and MCF-7 cells were provided by Donald Kufe (Dana-Farber Cancer Institute, Boston, MA). SW1990 and CAPAN2 human pancreatic carcinoma cells were provided by Andrew Warshaw (Massachusetts General Hospital). Primary human hepatocytes were prepared as described previously (21) . Human umbilical vascular endothelial cells were obtained from Cell Applications, Inc. (San Diego, CA). HSV-1 viruses F strain (wild-type HSV-1) and R3616 (defective {gamma}134.5 expression) were provided by Bernard Roizman (University of Chicago, Chicago, IL; Ref. 22 ). MGH1 is a HSV-1 mutant defective in thymidine kinase (TK) expression and viral ribonucleotide reductase (ICP6) expression and was provided by E. Antonio Chiocca (Massachusetts General Hospital). Viruses were propagated and titered on Vero cells, and heat-inactivation of virus was performed as described (23) .

Replication-Conditional HSV-1 Mutant with DF3/MUC1 Promoter.
The coding sequence of the {gamma}134.5 gene was isolated from pBGL34.5 (5) as a Nco-SacI fragment and cloned into pLitmus28 (New England BioLabs, Beverly, MA) by use of the same restriction sites. The DF3/MUC1 promoter, provided by Donald Kufe (Dana-Farber Cancer Institute, Boston, MA), was isolated from pDF3 (11) as a SpeI-XhoI fragment and subcloned into pCRII (Invitrogen, San Diego, CA) in the same sites. A NheI-SpeI fragment containing autofluorescence protein (AFP) regulated by a cytomegalovirus (CMV) promoter was isolated and subcloned into the SpeI locus of this plasmid. A NsiI-XhoI restriction fragment of this plasmid containing AFP regulated by a CMV promoter and the DF3/MUC1 promoter was then subcloned into the same sites of pLitmus28 with the DF3/MUC1 promoter immediately upstream of the {gamma}134.5 gene. This double-gene-expression cassette was then removed as a SpeI-KpnI fragment and subcloned into NheI and KpnI sites in pcDNA3.1(–) (Invitrogen). The cassette was then isolated as a BglII-PvuII fragment and subcloned into the BglII and SnaBI sites of HSV106 (kindly provided by Steven McNight, University of Texas Southwestern, Dallas, TX), such that the cassette is flanked by sequences of the HSV-1 TK gene. This plasmid was linearized with XbaI and cotransfected with R3616 viral DNA into Vero cells with Lipofectamine (Life Technologies, Inc., Gaithersburg, MD). Cells and media were collected 5–7 days after transfection when cytopathic effects were evident. Progeny virions were recovered from cells after three freeze-thaw cycles and then placed on a monolayer of Vero cells in the presence of ganciclovir. After the monolayer was overlaid with agarose, green fluorescent plaques were observed with fluorescence microscopy and selected as potential recombinants. Isolates were subjected to four rounds of plaque purification before their genetic identity was examined by Southern blot analysis.

Southern Blots.
Viral DNA was isolated after lysis of infected Vero cells with 0.5% SDS and proteinase K (500 µg/ml) by repeated phenol–chloroform extraction and ethanol precipitation. DNA was digested with PstI, separated by agarose gel electrophoresis, and transferred to a nylon membrane (Amersham Corp., Arlington Heights, IL). A probe to the TK gene was created by PCR amplification of HSV-1 DNA with the following primers: 5'-TACCCGAGCCGATGACTTACTG-3' and 5'-CCAACACCCGTGCGTTTTATTC-3'. A probe to the DF3/MUC1 promoter was created by PCR amplification of HSV-1 DNA using the following primers: 5'-AGAAGGGTGGGGCTATTCCG-3' and 5'-GCAGGTGACAGGTGACAAAACC-3'. PCR product were labeled with use of a random-prime labeling kit (Amersham Pharmacia Biotech, Piscataway, NJ) and purified in a spin column. After hybridization of the probe to the membrane, the membranes were washed and exposed to film.

Viral Replication and Cytotoxicity Assays.
Viral replication assays were performed as described (19) . Briefly, 3 x 106 cells were infected with 6 x 106 plaque forming units (pfu) of virus for 2 h, at which time unadsorbed virus was removed by washing with a glycine–saline solution (pH 3.0). Forty h after infection the supernatant and cells were harvested, exposed to three freeze–thaw cycles to release virions, and titered on Vero cells. Viral cytotoxicity assays were performed as described (18) . Briefly, cells were plated in 96-well plates at 5000 cells/well for 36 h. Virus was added at multiplicity of infection values ranging from 0.0001 to 10 and incubated for 6 days. The number of surviving cells was quantitated by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Experiments were performed three times in quadruplicate, and results of representative experiments are shown.

Elongation Initiation Factor 2{alpha} (eIF-2{alpha}) Dephosphorylation Assay.
This assay was performed as described previously (20) . Briefly, bacterial fusion proteins consisting of a His-tagged eIF-2{alpha} and glutathione-S-trans-ferase-tagged protein kinase R (PKR) were purified in nondenaturing conditions. Purified His-eIF-2{alpha} was reacted with glutathione-S-transferase-PKR in the presence of [{gamma}32P]ATP to radioactively label the His-eIF-2{alpha}. S10 fractions were prepared from infected or mock-infected cell lysates and reacted with the 32P-labeled His-eIF-2{alpha} at 32°C for 1 or 5 min. The proteins were resolved on 10–20% gradient gels, and the 32P remaining in eIF-2{alpha}-32P was quantified by an image analyzer (ImageQuant; Molecular Dynamics, Sunnyvale, CA). Experiments were performed three times, and results of representative experiments are shown.

Flow Cytometry.
Cells were washed with cold PBS, incubated with 1 µg/ml mouse antihuman CD-227 (kindly provided from Dr. Kufe) on ice for 30 min, and again washed with cold PBS. Cells were incubated with FITC-conjugated goat antimouse IgG (Biosource, Camarillo, CA) on ice for 30 min, washed with cold PBS, and then analyzed by flow cytometry. Fluorescence Intensity was determined for 2 x 104 cells.

Animal Studies.
Animal studies were performed in accordance with policies of the Massachusetts General Hospital. BALB/c (nu/nu) mice were obtained from Charles River Laboratories, Inc. (Wilmington, MA). LD50 was assessed by a single tail vein inoculation of 1 x 107, 5 x 107, 1 x 108, or 5 x 108 pfu of R3616, RH105, DF3{gamma}34.5, or F strain, after which the mice were followed for survival. In separate experiments, A375 or CAPAN2 tumors resected from mouse flanks were cut into 2-mm3 pieces and implanted s.c. in BALB/c (nu/nu) mouse flanks. Two weeks later, when the tumors measured 5 mm in diameter, 1 x 108 pfu RH105, MGH1, or DF3{gamma}34.5 or PBS was inoculated directly into the tumors (n = 6/group). Tumor sizes were measured every 5 days. Experiments were performed twice, and results of representative experiments are shown. In another set of experiments, F strain (5 x 106 pfu), RH105 (1 x 108 pfu), R3616 (1 x 108 pfu), or DF3{gamma}34.5 (1 x 108 pfu) was inoculated into flank tumors. Four days later mice were sacrificed, and organs were harvested for analysis of extracted DNA by PCR amplification of HSV-1 sequences.

PCR Assay.
PCR amplification of HSV-1-specific sequences to investigate the biodistribution of HSV-1 in mice was performed as described (20) . Forward oligonucleotide primer 5'-GGAGGCGCCCAAGCGTCCGGCCG-3' and reverse oligonucleotide primer 5'-TGGGGTACAGGCTGGCAAAGT-3' were used to amplify a 229-bp fragment of HSV-1 DNA polymerase gene. BALB/c mouse tissues were incubated in digestion buffer [10 mM Tris-HCl (pH 7.4), 5 mM EDTA, 0.5% SDS, 200 µg/ml proteinase K (pH 8.0)] at 56°C overnight. After phenol–chloroform (1:1) extraction, DNA was precipitated in 70% ethanol, lyophilized, and resuspended in distilled water. We then subjected 0.1 µg of DNA to PCR amplification. PCR reactions were performed in a 25-µl volume using rTth DNA polymerase according to the manufacturer’s instructions (Perkin-Elmer Applied Biosystems, Foster City, CA) in a DNA Thermal Cycler 480 (Perkin-Elmer Applied Biosystems). Cycling conditions were for 35 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min. Appropriate negative controls were used for all PCR reactions, and no contamination of reagents was detected.

Human Liver Tumors.
Wedge biopsies consisting of colon carcinoma liver metastases and surrounding normal liver were obtained fresh from the operating room in accordance with a protocol approved by the Massachusetts General Hospital Institutional Review Board. Small blood vessels were immediately cannulated and perfused with PBS. Through these same cannulas, either DF3{gamma}34.5 or F strain (1 x 108 pfu of either) was slowly injected into the liver section and allowed to dwell for 5 min. Uniform distribution throughout both normal liver and the metastases was confirmed with an injection of methylene blue. The liver was then sectioned into pieces measuring 5 mm in thickness and cultured in hepatocyte medium with 20% fetal bovine serum. Forty-eight h later portions of either the normal liver or liver metastases were dissected free, weighed, and homogenized in PBS containing collagenase (1 mg/ml). Dilutions were plated on monolayers of Vero cells to determine the titer of infectious virus in the tissues. This experiment was performed in four human liver specimens.

Statistical Analysis.
Two nonparametric statistical analyses, the log-rank test and Peto–Wilcoxon test, were used to compare survival between groups (InStat; Graphpad Software, New York, NY).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
HSV-1 Mutant with {gamma}134.5 Regulated by a DF3/MUC1 Promoter.
To develop a HSV-1 mutant with attenuated replication in MUC1-negative cells, we used a DF3/MUC1 promoter sequence to regulate {gamma}134.5 expression. We first constructed a plasmid containing an expression cassette in which {gamma}134.5 expression regulated by a DF3/MUC1 promoter sequence and an AFP gene is driven by a strong immediate-early CMV promoter (Fig. 1)Citation . Using homologous recombination techniques, we introduced this dual gene cassette into the TK locus of R3616, which is a HSV-1 mutant that harbors deletions in both {gamma}134.5 loci (22) . After four rounds of plaque purification, one isolate was selected and designated DF3{gamma}34.5. The genotype of this mutant was confirmed by Southern blot analysis.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Schematic diagrams and Southern blot analysis of DF3{gamma}34.5. The UL23 gene encodes Herpes simplex virus (HSV)-1 thymidine kinase (TK). The {gamma}134.5 genes are disrupted in the HSV-1 mutant R3616. pHSV106 contains the UL23 gene as well as sequences from flanking genes UL22 and UL24. A 3.9-kb expression cassette containing the {gamma}134.5 gene regulated by the DF3 promoter and the gene encoding the autofluorescence protein (AFP) marker regulated by a cytomegalovirus (CMV) promoter was subcloned into a SnaBI-BglII deletion from pHSV106. DF3{gamma}34.5 is the product of homologous recombination between this plasmid and R3616.

 
eIF-2{alpha} Phosphatase Activity in HSV-1-Infected Cells.
To assess {gamma}134.5 function in HSV-1 infected cells, we analyzed eIF-2{alpha} dephosphorylation in infected cells. eIF-2{alpha} is normally phosphorylated by PKR in response to HSV-1 infection, and HSV-1 {gamma}134.5 interacts with cellular protein phosphatase 1{alpha} to dephosphorylate eIF-2{alpha} to block the shutoff of protein synthesis (Fig. 2)Citation . We compared {gamma}134.5 function in cells infected by F strain (wild-type HSV-1), R3616 ({gamma}34.5-deficient), and DF3{gamma}34.5 ({gamma}34.5 expression regulated by the DF3/MUC1 promoter). A375 melanoma cells and Vero cells are DF3/MUC1-negative, whereas CAPAN2 cells are DF3/MUC1-positive (Fig. 3A)Citation . As expected, eIF-2{alpha} dephosphorylation activity was observed after infection with wild type (F strain) in all three cell lines because this virus expresses wild-type {gamma}134.5 (Fig. 3B)Citation . Also as expected, no eIF-2a dephosphorylation activity was observed after infection with R3616 (defective {gamma}134.5) in any of the three cell lines. Of note, eIF-2{alpha} dephosphorylation activity was observed with DF3{gamma}34.5 infection only in the DF3/MUC1-positive CAPAN2 cells, and not in the DF3/MUC1-negative A375 or Vero cells. This eIF-2{alpha} dephosphorylation pattern observed in cells infected by DF3{gamma}34.5 is consistent with regulation of {gamma}134.5 expression by the DF3/MUC1 promoter and represents one of the fundamental mechanisms by which we intend to regulate viral replication in this engineered HSV-1 mutant.



View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Elongation initiation factor 2{alpha} (eIF-2{alpha}) dephosphorylation in Herpes simplex virus-1 (HSV1)-infected cells. In response to viral double-strand RNA, protein kinase R (PKR) is activated by autophosphorylation. Activated PKR phosphorylates eIF-2{alpha}, which inhibits initiation of protein translation within the cell and in turn inhibits viral replication. HSV-1 {gamma}134.5 interacts with cellular protein phosphatase-1{alpha} (PP1{alpha}) to dephosphorylate eIF-2{alpha}, thus allowing continued protein synthesis.

 


View larger version (54K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Herpes simplex virus-1 (HSV-1) replication in cells that differ in expression of DF3/MUC1. A, fluorescence-activated cell-sorting analysis of DF3/MUC1 expression in carcinoma cell lines demonstrates that MCF-7 (breast carcinoma), CAPAN2 (pancreas carcinoma), and SW1990 (colon carcinoma) express DF3/MUC1, whereas A375 (melanoma), Vero (normal kidney cells), and human umbilical vascular endothelial cells (HUVEC; normal endothelial cells) do not. B, lysates prepared from cells infected with HSV-1 mutants were reacted with 32P-labeled elongation initiation factor 2{alpha} (eIF-2{alpha}). The decrease in intensity of the eIF-2{alpha} band after 5 min of reaction time (relative to time 1 min) is proportional to eIF-2{alpha} dephosphorylation activity in the lysate. C, HSV-1 replication was assessed in three DF3/MUC1-positive and three DF3/MUC1-negative cell lines by use of a single-step replication assay. D, cytotoxicity induced by DF3{gamma}34.5, RH105, MGH1, and R3616 was assessed in vitro. The cells in the left-hand column (A375, Vero, and HUVEC) are DF3/MUC1-negative. The cells in the right-hand column (MCF-7, CAPAN2, and SW1990) are DF3/MUC1-positive.

 
DF3{gamma}34.5 Replication and Cytotoxicity.
We compared DF3{gamma}34.5 replication with that of other HSV-1 mutants in DF3/MUC1-negative and -positive cells. HSV-1 mutants used for comparison were R3616 ({gamma}134.5–), RH105 (UL23–), and MGH1 ({gamma}134.5– and UL39–; Table 1Citation ). The intended phenotype of DF3{gamma}34.5 is for its replication to be more attenuated than that of R3616 and RH105 in DF3/MUC1-negative cells because of its deficient expression of both TK and {gamma}134.5 in these cells. DF3{gamma}34.5 should also replicate as robustly as either R3616 or RH105 in DF3/MUC1-positive cancer cells because of its expression of functional {gamma}134.5 gene product in these cells.


View this table:
[in this window]
[in a new window]

  		Table 1 Herpes simplex virus-1 mutants

 
In DF3/MUC1-negative cells, we observed that DF3{gamma}34.5 replication was as attenuated as that of MGH1 replication (double mutant) and more attenuated than both R3616 and RH105 (Fig. 3C)Citation . In the DF3/MUC1-positive cells, DF3{gamma}34.5 replication was equivalent to that of the TK-defective RH105 in CAPAN2 cells, but was one-half log order less than RH105 in the other DF3/MUC1-positive cells (MCF-7 and SW1990). Of note, based on its design, DF3{gamma}34.5 replication should not exceed that of RH105; in DF3/MUC1-positive cells DF3{gamma}34.5 replication is expected to at best be equivalent to that of RH105. We also observed that DF3{gamma}34.5 replication was approximately one log order greater than that of R3616 in DF3/MUC1-positive cells and one log order less than that of R3616 in MUC1-negative cells. These results suggest that DF3{gamma}34.5 replication is regulated by restriction of {gamma}134.5 function to DF3/MUC1-positive cells as intended, thereby resulting in attenuated replication in DF3/MUC1-negative cells relative to DF3/MUC1-positive cells.

We next examined whether DF3{gamma}34.5-induced cytotoxicity in vitro also followed a pattern that correlated with DF3/MUC1 expression. Cells were infected with each of the HSV-1 mutants at increasing multiplicity of infection values, and cell survival was assessed 6 days later. In the DF3/MUC1-positive cells, DF3{gamma}34.5 was as oncolytic as RH105 ({gamma}134.5+) and more oncolytic than R3616 ({gamma}134.5–). In the DF3/MUC1-negative cells, DF3{gamma}34.5 was more attenuated than both RH105 and R3616 and as attenuated as the double mutant MGH1 at low multiplicity of infection values (Fig. 3D)Citation . These data are consistent with DF3{gamma}34.5 replication and oncolysis being dependent on DF3/MUC1 expression.

It was not possible to examine the specificity of the human DF3 promoter in mouse models; accordingly, we devised an assay to examine in human tissues how this promoter regulates DF3{gamma}34.5 replication. Human liver biopsy specimens, each containing a small colon carcinoma metastasis and surrounding normal liver, were harvested fresh from the operating room. As expected, immunohistochemical staining revealed DF3/MUC1 expression in the metastases and not in the normal liver (data not shown). Small blood vessels were cannulated to inject either F strain or DF3{gamma}34.5. The specimen was then cut into pieces measuring 5 mm in thickness and incubated in medium for 72 h, at which time examination of the slices infected with DF3{gamma}34.5 revealed green fluorescence (indicative of viral replication and marker transgene expression) preferentially in the metastases rather than the normal liver (Fig. 4A)Citation . Moreover, although the titers of F strain recovered from normal liver tissue were similar to titers recovered from liver metastases, titers of DF3{gamma}34.5 were two log orders lower in the normal liver than in the metastases (Fig. 4B)Citation . These data demonstrate preferential replication of DF3{gamma}34.5 in liver metastases compared with normal liver after intravascular perfusion of human liver specimens.



View larger version (78K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Replication of F strain (wild type) and DF3{gamma}34.5 in specimens of human liver and colon carcinoma. A, specimens of human liver containing colon carcinoma metastases were perfused with DF3{gamma}34.5 and subjected to phase-contrast (top) or fluorescent (bottom) microscopy 72 h later. Photographs are x100 magnification. Autofluorescence protein expression (green) is significantly greater in the central tumor nodule than in the surrounding normal liver. B, portions of the normal liver or colon cancer metastases that had been infused with either F strain or DF3{gamma}34.5 were weighed, homogenized, and titered for infectious virus. pfu, plaque-forming units.

 
HSV-1 Oncolysis of Flank Tumor Xenografts.
We examined antineoplastic efficacy in vivo against DF3/MUC1-positive CAPAN2 flank tumors and DF3/MUC1-negative A375 flank tumors. Tumors were directly inoculated with virus every third day for a total of four inoculations, and tumor sizes were measured every 5 days. In both tumor models, DF3{gamma}34.5 demonstrated greater antineoplastic effects than that of mock-infected medium (control mice; Fig. 5Citation ). In addition, the antineoplastic effect of DF3{gamma}34.5 was greater than that of the control RH105 virus in DF3/MUC1-positive CAPAN2 tumors and less than that of RH105 in DF3/MUC1-negative A375 tumors. As expected in the A375 tumors, DF3{gamma}34.5 was as attenuated as the double mutant MGH1. These data are consistent with our in vitro observations and provide further evidence that DF3{gamma}34.5 replication and consequent antineoplastic activity are regulated by the DF3/MUC1 promoter.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Herpes simplex virus-1 (HSV-1) oncolysis of flank tumor xenografts. Tumor volumes were measured in BALB/c (nu/nu) mice bearing either A375 or CAPAN2 flank tumors that were inoculated once with DF3{gamma}34.5 ({diamond}), RH105 ({circ}), MGH1 ({square}), or mock-infected medium (PBS; {triangleup}). For A375 (top), P = 0.002 for DF3{gamma}34.5 versus RH105; and P = 0.32 for DF3{gamma}34.5 versus MGH1. For CAPAN2 (bottom), P = 0.013 for DF3{gamma}34.5 versus RH105; and P = 0.002 for DF3{gamma}34.5 versus MGH1. Bars, SD.

 
LD50 and Biodistribution in Mice.
On the basis of our observation that DF3{gamma}34.5 replication is more attenuated than that of R3616 and RH105 in MUC1-negative cells, we examined whether this correlated with a lower LD50 after i.v. inoculation. Cohorts of mice received injections of F strain, DF3{gamma}34.5, R3616, or RH105. Mice receiving the higher doses commonly developed paralysis followed by death within 5 days (Table 2)Citation . As has been demonstrated previously, wild-type F strain was the most virulent, with all mice rapidly dying at the lowest dose examined, whereas the single-site mutants R3616 and RH105 were more attenuated in virulence. Notably, the LD50 of DF3{gamma}34.5 was one-half to one full log order greater than that of mutants R3616 and RH105. This reduction in pathological virulence of DF3{gamma}34.5 observed after i.v. inoculation was associated with a more restricted biodistribution as assessed by PCR analysis of harvested organs (Table 3)Citation .


View this table:
[in this window]
[in a new window]

  		Table 2 Survival after tail vein inoculation of Herpes simplex virus-1

 

View this table:
[in this window]
[in a new window]

  		Table 3 Sites of Herpes simplex virus-1 infection as assessed by PCR

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Replication-competent viruses have many advantages over replication-defective viruses for cancer therapy applications. Because progeny virions can infect adjacent cells, it is not necessary to infect all tumor cells initially, and vector distribution increases over time (24) . In contrast, the distribution of transgene expression is much more restricted after direct intratumoral inoculation of replication-defective vectors. Another benefit of replication-competent viruses is that the maximum "dose" is greater than the input dose as a result of in vivo amplification. Incorporation of a therapeutic transgene within the genome of a replication-competent virus permits a two-pronged cancer therapy strategy: oncolysis by viral replication together with the effects of therapeutic transgene expression (25 , 26) . However, careful selection of therapeutic transgenes is necessary to avoid the problem of antagonism between transgene expression and viral replication (25 , 27) . The combination of viral oncolysis with therapeutic transgene expression may reduce the risk of emergence of tumor cell resistance to therapy.

One of the greatest challenges faced in the field of viral oncolysis is the development of successful strategies to maximize viral replication in tumor cells and minimize replication in normal cells. Several approaches to restrict viral replication to cancer cells have been examined. The simplest strategy is to inoculate the virus directly into the tumor. This approach has several drawbacks, including the inability to treat radiographically or visually occult lesions and the inability to distribute the virus homogeneously throughout the tumor. Another strategy involves modulation of the interaction between virus and cell surface receptors to permit viral entry into tumor cells but not normal cells. The most well-known example of this strategy is modification of the adenovirus fiber to overcome tumor cell down-regulation of the viral entry receptor CAR (28) . A third strategy involves exploitation of the natural properties of some viruses to infect and replicate specifically within cancer cells. The natural selectivity of Newcastle disease virus and vesiculostomatitis virus for cancer cells appears to be a result of defects in the IFN signaling pathways that are commonly present in cancer cells but intact in normal cells (29 , 30) . Another strategy involves removal of genes from a virus that are critical for replication in normal cells but whose absence is functionally complemented in neoplastic cells. The E1b 55-kDa protein is not expressed in cells infected by the adenoviral mutant Onyx-015 (31) . In the absence of E1B55kD protein, viral replication is attenuated except in cells in which the p53 pathway is already disrupted.

In this study we restricted viral replication by regulation of the HSV-1 {gamma}134.5 gene by a promoter sequence for a tumor-associated antigen. {gamma}134.5 plays a critical role in aiding HSV-1 to subvert an important cellular defense after infection, i.e., PKR activation (32 , 33) . The importance of this defense mechanism against viral infection has been affirmed by the observation that most viruses have incorporated strategies to overcome the shutoff of protein translation that accompanies PKR activation. Adenovirus expresses VAI RNA to inhibit PKR activation (34) . Similarly, human immunodeficiency virus produces TAR RNA, which performs a function similar to that of VAI RNA (35) . Influenza virus stabilizes a cellular inhibitor of PKR that forms after infection, thereby functionally inhibiting PKR (36 , 37) , and as another example, the E3L and NS5A proteins that are expressed by HCV are known inhibitors of PKR (38) . HSV-1 circumvents the consequences of PKR activation by expression of {gamma}134.5 (Fig. 2)Citation , which has sequences homologous with the GADD34 protein (39) .

DF3/MUC1 overexpression is observed in many human carcinomas, and mRNA overexpression has been observed in breast carcinomas (40) . Abe and Kufe (10) identified elements in the DF3/MUC1 5' region responsible for regulating transcription. The strength and specificity of this promoter has been demonstrated previously by its ability to appropriately restrict transgene expression to DF3/MUC1-positive cells (41) . Selectivity of this promoter sequence has also been demonstrated in an adenoviral construct in which E1A expression was regulated by the DF3/MUC1 promoter (11) .

We observed that replication of the HSV-1 mutant DF3{gamma}34.5 is attenuated in DF3/MUC1-negative cells relative to DF3/MUC1-positive cells. This attenuation was associated with a more restricted pattern of biodistribution in mice after treatment of flank xenografts and was also associated with a higher LD50 dose in mice. An important limitation in the interpretation of these data is that the human DF3/MUC1 promoter is not expected to function in mice as it does in humans. The hypothesis that the attenuated toxicity of DF3{gamma}34.5 in humans mirrors that observed in mice necessarily requires examination in a clinical trial. Human gene therapy phase trials are exceedingly costly; we therefore developed an assay to examine viral replication in human tissues. Our observation that DF3{gamma}34.5 replication is attenuated in normal human liver relative to colon cancer liver metastases after perfusion of a portion of the organ lends credence to the notion that DF3{gamma}34.5 would behave similarly after intravascular administration into patients’ livers. We used this organ perfusion experimental model to examine HSV-1 replication; however, it is clearly applicable to examination of other viruses and other therapeutic agents. Conceivably, similar models using portions of other human organs can be developed.

DF3{gamma}34.5 itself is not suitable for examination in clinical trials because it is not susceptible to ganciclovir or acyclovir as a result of inactivation of its TK gene. Sensitivity to these therapeutic agents is an important safety feature to limit unwanted viral replication. We selected the TK locus for homologous recombination because of the ease with which recombinants can be selected with ganciclovir and because we are interested mainly in testing principles. Despite the availability of other antiherpetic agents to which these TK-defective viruses should be sensitive, DF3{gamma}34.5 is not suitable for clinical trials without repair of the TK gene.

The strategic decision of which promoter to use is important to the success of this strategy. For this study, we selected a DF3/MUC1 promoter sequence that has previously been demonstrated to effectively regulate adenoviral replication (11) . The choice of location in the HSV-1 genome in which to place the heterologous promoter is equally important. Use of a carcinoembryonic antigen (CEA) promoter in the UL39 locus to regulate ICP4 expression does not result in preferential HSV-1 replication in CEA-positive cells (42) . cis interactions in the region of the promoter may affect the specificity of transcriptional regulation. Others have successfully regulated gene expression within the UL23 (TK) locus (43) , and this observation strongly influenced our decision to use this locus. Finally, the strategic decision of which HSV-1 gene to regulate with the heterologous promoter is important; the gene product ideally should be one whose absence is not effectively complemented in normal cells.

Replication-competent viruses offer several advantages over replication-defective viruses for cancer gene therapy applications. The success with which replication-competent viruses can treat cancer will very likely be dependent on the ability to achieve replication preferentially in neoplastic cells rather than normal cells. Our results demonstrate that the DF3/MUC1 promoter regulates {gamma}134.5 expression within the context of HSV-1 replication in a manner that effectively attenuates viral replication in DF3/MUC1-negative cells but permits effective destruction of tumors. Because DF3/MUC1 is overexpressed in a broad spectrum of carcinomas, this approach to viral oncolysis may be broadly applicable.


   FOOTNOTES
 
Grant support: NIH Grants CA64454 and CA76183 (K. K. Tanabe), GM07035 (T. M. Pawlik), DK43352 (core facilities), and CA71345 (J. T. Mullen), and the Claude E. Welch Research Fellowship (J. T. Mullen).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Kenneth K. Tanabe, Cox Building 626, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114.

Received 11/ 3/03. Accepted 1/23/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rosenberg SA, Blaese RM, Brenner MK, et al Human gene marker/therapy clinical protocols. Hum Gene Ther, 11: 919-79, 2000.[CrossRef][Medline]
  2. Martuza RL Conditionally replicating herpes vectors for cancer therapy. J Clin Investig, 105: 841-6, 2000.[Medline]
  3. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res, 57: 2559-63, 1997.[Abstract/Free Full Text]
  4. Li Y, Yu DC, Chen Y, et al A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res, 61: 6428-36, 2001.[Abstract/Free Full Text]
  5. Chung RY, Saeki Y, Chiocca EA B-myb promoter retargeting of herpes simplex virus {gamma}34.5 gene-mediate virulence toward tumor and cycling cells. J Virol, 73: 7556-64, 1999.[Abstract/Free Full Text]
  6. Abe M, Kufe DW Identification of a family of high molecular weight tumor-associated glycoproteins. J Immunol, 139: 257-61, 1987.[Abstract]
  7. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma, 3: 223-32, 1984.[Medline]
  8. Friedman EL, Hayes DF, Kufe DW Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res, 46: 5189-94, 1986.[Abstract/Free Full Text]
  9. Abe M, Kufe D Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. J Cell Physiol, 143: 226-31, 1990.[CrossRef][Medline]
  10. Abe M, Kufe D Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA, 90: 282-6, 1993.[Abstract/Free Full Text]
  11. Kurihara T, Brough DE, Kovesdi I, Kufe DW Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Investig, 106: 763-71, 2000.[Medline]
  12. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Wash DC), 252: 854-6, 1991.[Abstract/Free Full Text]
  13. Kooby DA, Carew JF, Halterman MW, et al Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J, 13: 1325-34, 1999.[Abstract/Free Full Text]
  14. Nakamura H, Honda Y, Tsuiki H, et al Molecular cloning of a novel human nucleoside diphosphate kinase by functional complementation of p53-mediated apoptosis. Proc Am Assoc Cancer Res, 38: 1997.
  15. Markert JM, Medlock MD, Rabkin SD, et al Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther, 7: 867-74, 2000.[CrossRef][Medline]
  16. Kesari S, Randazzo BP, Valyi Nagy T, et al Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Investig, 73: 636-48, 1995.[Medline]
  17. Rampling R, Cruickshank G, Papanastassiou V, et al Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther, 7: 859-66, 2000.[CrossRef][Medline]
  18. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg, 224: 323-30, 1996.[CrossRef][Medline]
  19. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J, 14: 301-11, 2000.[Abstract/Free Full Text]
  20. Nakamura H, Kasuya H, Mullen JT, et al Regulation of herpes simplex virus g134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Investig, 109: 871-82, 2002.[CrossRef][Medline]
  21. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK Cancer gene therapy using replication-competent herpes simplex virus type 1. Ann Surg, 228: 366-74, 1998.[CrossRef][Medline]
  22. Chou J, Kern ER, Whitley RJ, Roizman B Mapping of herpes simplex virus-1 neurovirulence to {gamma}134.5, a gene nonessential for growth in culture. Science (Wash DC), 250: 1262-6, 1990.[Abstract/Free Full Text]
  23. Lelie PN, Reesink HW, Lucas CJ Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J Med Virol, 23: 297-301, 1987.[Medline]
  24. Ichikawa T, Chiocca EA Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res, 61: 5336-9, 2001.[Abstract/Free Full Text]
  25. Chase M, Chung R, Chiocca EA An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotech, 16: 444-8, 1998.[CrossRef][Medline]
  26. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res, 61: 5447-52, 2001.[Abstract/Free Full Text]
  27. Pawlik TM, Nakamura H, Yoon SS, et al Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res, 60: 2790-5, 2000.[Abstract/Free Full Text]
  28. Haviv YS, Blackwell JL, Kanerva A, et al Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res, 62: 4273-81, 2002.[Abstract/Free Full Text]
  29. Stojdl DF, Lichty B, Knowles S, et al Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med, 6: 821-5, 2000.[CrossRef][Medline]
  30. Rizvi N, Cohen GI, Meropol NJ, et al Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. J Clin Oncol, 20: 2251-66, 2002.[Abstract/Free Full Text]
  31. Bischoff JR, Kirn DH, Williams A, et al An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash DC), 274: 373-6, 1996.[Abstract/Free Full Text]
  32. Ghadge GD, Malhotra P, Furtado MR, Dhar R, Thimmapaya B In vitro analysis of virus-associated RNA I (VAI RNA): inhibition of the double-stranded RNA-activated protein kinase PKR by VAI RNA mutants correlates with the in vivo phenotype and the structural integrity of the central domain. J Virol, 68: 4137-51, 1994.[Abstract/Free Full Text]
  33. Jagus R, Joshi B, Barber GN PKR, apoptosis and cancer. Int J Biochem Cell Biol, 31: 123-38, 1999.[CrossRef][Medline]
  34. Park H, Davies MV, Langland JO, et al TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci USA, 91: 4713-7, 1994.[Abstract/Free Full Text]
  35. Lee TG, Tang N, Thompson S, Miller J, Katze MG The 58,000-Dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins. Mol Cell Biol, 14: 2331-42, 1994.[Abstract/Free Full Text]
  36. Gale MJ, Jr., Korth MJ, Tang NM, et al Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology, 230: 217-27, 1997.[CrossRef][Medline]
  37. Tang NM, Ho CY, Katze MG The 58-kDa cellular inhibitor of the double stranded RNA-dependent protein kinase requires the tetratricopeptide repeat 6 and DnaJ motifs to stimulate protein synthesis in vivo. J Biol Chem, 271: 28660-6, 1996.[Abstract/Free Full Text]
  38. Davies MV, Chang HW, Jacobs BL, Kaufman RJ The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol, 67: 1688-92, 1993.[Abstract/Free Full Text]
  39. He B, Gross M, Roizman B The {gamma}(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1{alpha} to dephosphorylate the {alpha} subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA, 94: 843-8, 1997.[Abstract/Free Full Text]
  40. Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA, 87: 9498-502, 1990.[Abstract/Free Full Text]
  41. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Investig, 96: 2775-82, 1995.
  42. Mullen JT, Kasuya H, Yoon SS, et al Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg, 236: 502-12, 2002.[CrossRef][Medline]
  43. Miyatake S, Iyer A, Martuza RL, Rabkin SD Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol, 71: 5124-32, 1997.[Abstract]
  44. Ejercito PM, Kieff ED, Roizman B Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol, 2: 357-64, 1968.[Abstract/Free Full Text]
  45. Nilaver G, Kroll RA, Pagel MA, et al Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Am J Path, 147: 1840-51, 1995.[Abstract]
  46. Kramm CM, Chase M, Herrlinger U, et al Therapeutic efficiency and safety of a second-generation replication- conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther, 8: 2057-68, 1997.[Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe
Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis
Cancer Res., April 1, 2007; 67(7): 3295 - 3300.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kambara, H. Okano, E. A. Chiocca, and Y. Saeki
An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain Tumor
Cancer Res., April 1, 2005; 65(7): 2832 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
E. A. Chiocca
Oncolytic Viral Therapeutics Based on Herpes Simplex Virus Type I
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 139 - 140.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Wang, S. Thorne, J. Hannock, J. Francis, T. Au, T. Reid, N. Lemoine, D. Kirn, and G. Hallden
A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses
Clin. Cancer Res., January 1, 2005; 11(1): 351 - 360.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasuya, H.
Right arrow Articles by Tanabe, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasuya, H.
Right arrow Articles by Tanabe, K. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online